Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

36.52 +0.61 (+1.70%)

Streaming Delayed Price Updated: 1:25 PM EDT, Jun 24, 2026 Add to My Watchlist

Price and Volume

Volume	816,882
Open	36.40
Bid (Size)	36.50 (200)
Ask (Size)	36.58 (300)
Prev. Close	35.91
Today's Range	36.09 - 37.66
52wk Range	25.83 - 57.99
Shares Outstanding	54,026,103
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

June 14, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

June 14, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	-21.8%	-21.8%
1 Month	-0.7%	-0.7%
3 Month	+6.3%	+6.3%
6 Month	-25.3%	-25.3%
1 Year	+22.1%	+22.1%

More News

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

June 02, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

June 02, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

May 22, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals (NASDAQ:CRNX) Beats Q1 Expectations on Strong PALSONIFY Launch, Stock Slips After Hours ↗

May 07, 2026

Via Chartmill

Crinetics Pharmaceuticals (NASDAQ:CRNX) Beats Q4 Revenue Estimates on First Product Sales ↗

February 26, 2026

Via Chartmill

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗

May 18, 2026

Via The Motley Fool

Crinetics (CRNX) Q1 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 07, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

April 27, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More ↗

March 27, 2026

Via The Motley Fool

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

March 26, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗

March 13, 2026

Via The Motley Fool

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗

March 13, 2026

Via The Motley Fool

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗

March 13, 2026

Via The Motley Fool

Crinetics (CRNX) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Via The Motley Fool

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 26, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

February 05, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology

January 28, 2026

Via Finterra

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

January 26, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

January 22, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

The market is filled with gapping stocks in Wednesday's session. ↗

January 07, 2026

Via Chartmill

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

January 06, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Crinetics Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Crinetics Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Crinetics Pharmaceuticals, Inc. - Common Stock trade on?

Crinetics Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock is CRNX on the Nasdaq Stock Market

What is the current price of Crinetics Pharmaceuticals, Inc. - Common Stock?

The current price of Crinetics Pharmaceuticals, Inc. - Common Stock is 36.52

When was Crinetics Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Crinetics Pharmaceuticals, Inc. - Common Stock was at 06/24/26 01:25 PM ET

What is the market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock is 1.97B

How many shares of Crinetics Pharmaceuticals, Inc. - Common Stock are outstanding?

Crinetics Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.